NCT05351047 is a Phase 1 clinical trial of AZD2373 subcutaneous injection in Healthy Volunteers, sponsored by AstraZeneca.

Who is sponsoring NCT05351047?

NCT05351047 is sponsored by AstraZeneca.

What drugs are being tested in NCT05351047?

Interventions in NCT05351047: AZD2373 subcutaneous injection, Placebo.

What condition does NCT05351047 study?

NCT05351047 studies Healthy Volunteers.

Is NCT05351047 still recruiting?

NCT05351047 is currently completed. Last updated 7 August 2023.

Last reviewed 2023-08-07 · How we verify

NCT05351047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Completed Phase 1 Last updated 7 August 2023

What this trial tests

Phase 1 trial testing AZD2373 subcutaneous injection in Healthy Volunteers in 24 participants. Completed in 6 July 2023.

Timeline

4 April 2022

Primary endpoint
6 July 2023

6 July 2023

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	4 April 2022
Primary completion	6 July 2023
Estimated completion	6 July 2023
Sites	1 location across United States

Drugs / interventions tested

AZD2373 subcutaneous injection — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of sub-Saharan West African ancestry.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f
Novel Therapies in <i>APOL1</i>-Mediated Kidney Disease: From Molecular Pathways to Therapeutic Options.
Vasquez-Rios G, De Cos M, Campbell KN. · · 2023 · cited 19× · PMID 38025220 · DOI 10.1016/j.ekir.2023.08.028
RNA-Based Therapies in Kidney Diseases.
Hu L, Jin T, Zhang N, Ding J, et al · · 2025 · cited 4× · PMID 40059951 · DOI 10.2147/jir.s505252
APOL1 nephropathy - a population genetics success story.
Tabachnikov O, Skorecki K, Kruzel-Davila E. · · 2024 · cited 4× · PMID 38415700 · DOI 10.1097/mnh.0000000000000977
Kidney Disease in the Caribbean-APOL1 Risk Alleles and Emerging Environmental Stressors.
Myrie J, Soyibo A, Friedman D, Anand S, et al · · 2024 · cited 3× · PMID 39081772 · DOI 10.1016/j.ekir.2024.04.071
APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.
Adebayo OC, Okpoli HC, Vriens J, Levtchenko E, et al · · 2025 · cited 1× · PMID 41402748 · DOI 10.1186/s12882-025-04687-y

Verify or expand the search:

Other trials of AZD2373 subcutaneous injection

Trials testing the same drug.

NCT04269031 — A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05351047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 7 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05351047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing